pharma · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · RLMD
RELMADA THERAPEUTICS
RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker RLMD. Primary therapeutic focus areas include Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urot
Company details
- Status
- Public
- HQ
- Coral Gables, USA
- Founded
- 2004
- Employees
- 33
- Programs
- 6
- Drugs
- 5
- Patents
- 7
NDV-01 (sustained-release gemcitabine-docetaxel)
Phase 3 · small molecule · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
NDV-01 (sustained-release gemcitabine-docetaxel) for Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) is a Phase 3 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code REL-NDV01-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- RELMADA THERAPEUTICS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- Status
- terminated
- Trials
- 1